ImmunoGen Inc. discovers and develops therapeutic monoclonal antibodies and novel treatments in the field of oncology. Its lead technology, which it refers to as tumor-activated prodrug, uses antibodies to deliver potent cell-killing agents specifically to cancer cells.

View SEC Filings from IMGN instead.
Filers who had this stock in their top 10: 0
13F Filers holding this stock: 153
Aggregate shares on 09/30/2016: 73,908,265
Aggregate shares on 06/30/2016: 80,008,020
Percent change: -7.62%
Funds creating new positions: 21
Funds Adding to an existing position: 32
Funds closing out their position: 21
Funds reducing their position: 57
View recent insider trading info

13F Filers holding this stock

Quarter 1: Refresh

Changes in Holdings:

*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Schedule 13D and 13G filings submitted since 09/30/2016

Subscription required

Click here to report any possible errors with this stock listing.

Elevate your investments

or Learn more